30 October 2014

Share Purchase Plan Closing Tomorrow 31 October 2014

Antisense Therapeutics Limited ("ANP" or "the Company") reminds eligible shareholders that its share purchase plan (SPP) will close at 5.00pm tomorrow, Friday 31 October 2014.

Eligible shareholders that wish to participate in the share purchase plan should ensure that their application is submitted by that time. Shareholders who require a new SPP Application Form, please call the Antisense Therapeutics Shareholder Information Line on **1300 737 760** (within Australia) or +61 2 9290 9600 (International) or via email on corporateactions@boardroomlimited.com.au.

Pursuant to the SPP, eligible shareholders are entitled to purchase up to $15,000 worth of fully paid ordinary shares in the Company at an issue price of 11.5 cents per share without any brokerage or transaction costs. The first $1 million of the SPP is underwritten by Patersons Securities Limited. The terms and conditions of the SPP, including the underwriting arrangements, are set out in the offer letter announced and dispatched to shareholders on 7 October 2014.

The timetable of key dates for the SPP is as follows:

Record Date	Wednesday 24 September 2014
Closing Date	31 October 2014
Annual General Meeting of Shareholders	Thursday 6 November 2014
Allotment of Shares	Wednesday 12 November 2014

Contact Information:
Website: www.antisense.com.au
Company Secretary & CFO: Phillip Hains +61 (0)408 579 121
Australian Investor/Media: Annabel Murphy+61 (0)2 9237 2800; amurphy@buchanwe.com.au

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. ANP has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals Inc., world leaders in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS) , ATL1103 a second-generation antisense drug designed to block GHr production which in a Phase II clinical trial, successfully reduced blood IGF-I levels in patients with the growth disorder acromegaly, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.